Show simple item record

dc.contributor.authorMilighetti, M
dc.contributor.authorKrasny, L
dc.contributor.authorLee, ATJ
dc.contributor.authorMorani, G
dc.contributor.authorSzecsei, C
dc.contributor.authorChen, Y
dc.contributor.authorGuljar, N
dc.contributor.authorMcCarthy, F
dc.contributor.authorWilding, CP
dc.contributor.authorArthur, A
dc.contributor.authorFisher, C
dc.contributor.authorJudson, I
dc.contributor.authorThway, K
dc.contributor.authorCheang, MCU
dc.contributor.authorJones, RL
dc.contributor.authorHuang, PH
dc.date.accessioned2021-07-02T11:10:59Z
dc.date.available2021-07-02T11:10:59Z
dc.identifier.citationJournal of proteomics, 2021, 241 pp. 104236 - ?
dc.identifier.issn1874-3919
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4667
dc.identifier.eissn1876-7737
dc.identifier.doi10.1016/j.jprot.2021.104236
dc.description.abstractSoft tissue sarcomas (STS) are a group of rare and heterogeneous cancers. While large-scale genomic and epigenomic profiling of STS have been undertaken, proteomic analysis has thus far been limited. Here we utilise sequential window acquisition of all theoretical fragment ion spectra mass spectrometry (SWATH-MS) for proteomic profiling of formalin fixed paraffin embedded (FFPE) specimens from a cohort of STS patients (n = 36) across four histological subtypes (leiomyosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma). We quantified 2951 proteins across all cases and show that there is a significant enrichment of gene sets associated with smooth muscle contraction in leiomyosarcoma, RNA splicing regulation in synovial sarcoma and leukocyte activation in undifferentiated pleomorphic sarcoma. We further identified a subgroup of STS cases that have a distinct expression profile in a panel of proteins, with worse survival outcomes when compared to the rest of the cohort. Our study highlights the value of comprehensive proteomic characterisation as a means to identify histotype-specific STS profiles that describe key biological pathways of clinical and therapeutic relevance; as well as for discovering new prognostic biomarkers in this group of rare and difficult-to-treat diseases.
dc.formatPrint-Electronic
dc.format.extent104236 - ?
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectLeiomyosarcoma
dc.subjectSarcoma
dc.subjectGene Expression Profiling
dc.subjectProteomics
dc.subjectMass Spectrometry
dc.titleProteomic profiling of soft tissue sarcomas with SWATH mass spectrometry.
dc.typeJournal Article
dcterms.dateAccepted2021-04-14
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1016/j.jprot.2021.104236
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal of proteomics
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Genomic Analysis – Clinical Trials
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Genomic Analysis – Clinical Trials
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume241
pubs.embargo.termsNot known
icr.researchteamGenomic Analysis – Clinical Trials
icr.researchteamSarcoma Clinical Trials (R Jones)
icr.researchteamMolecular and Systems Oncology
icr.researchteamGenomic Analysis – Clinical Trialsen_US
icr.researchteamSarcoma Clinical Trials (R Jones)en_US
icr.researchteamMolecular and Systems Oncologyen_US
dc.contributor.icrauthorHuang, Paulen
dc.contributor.icrauthorCheang, Chonen
dc.contributor.icrauthorJones, Robinen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0